The kinase NIK as a therapeutic target in multiple myeloma

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 2, 2011, Pages 207-218

  Gardam, Sandra ^a   Beyaert, Rudi ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

cancer; inhibitor; MAP3K14; multiple myeloma; NF B; NIK; therapy

Indexed keywords

6 AZAINDOLE AMINOPYRIMIDINE; CIAP PROTEIN; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; PYRIMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MODULATION; MOLECULAR STABILITY; MULTIPLE MYELOMA; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

B-LYMPHOCYTES; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 78651375086     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.548861     Document Type: Review

References (96)

1. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-16
2. Staudt LM. Oncogenic activation of NF-kB. Cold Spring Harb Perspect Biol 2010;2(6):a000109
3. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997;385:540-4
4. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-44
5. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-30
6. Fan CM, Maniatis T. Generation of p50 subunit of NF-kappaB by processing of p105 through an ATP-dependent pathway. Nature 1991;354:395-8
7. Mellits KH, Hay RT, Goodbourn S. Proteolytic degradation of MAD3 (IkappaBalpha) and enhanced processing of the NF-kappaB precursor p105 are obligatory steps in the activation of NF-kappaB. Nucleic Acids Res 1993;21:5059-66
8. Mercurio F, DiDonato JA, Rosette C, Karin M. p105 and p98 precursor proteins play an active role in NF-kappaB-mediated signal transduction. Genes Dev 1993;7:705-18
9. Blank V, Kourilsky P, Israel A. Cytoplasmic retention, DNA binding and processing of the NF-kappaB p50 precursor are controlled by a small region in its C-terminus. EMBO J 1991;10:4159-67
10. Verma IM, Stevenson JK, Schwarz EM, et al. Rel/NF-kappaB/IkappaB family: intimate tales of association and dissociation. Genes Dev 1995;9:2723-35
11. Senftleben U, Cao Y, Xiao G, et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappaB signaling pathway. Science 2001;293:1495-9
12. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988;242:540-6
13. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002;3:20-6
14. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 1999;284:309-13
15. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 2006;25:6685-705
16. Coope HJ, Atkinson PG, Huhse B, et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002;21:5375-85
17. Lin X, Mu Y, Cunningham ET Jr, et al. Molecular determinants of NF-kappaB-inducing kinase action. Mol Cell Biol 1998;18:5899-907
18. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001;7:401-9
19. Ling L, Cao Z, Goeddel DV. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci USA 1998;95:3792-7
20. Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem 2004;279:30099-105
21. Liang C, Zhang M, Sun SC. Beta-TrCP binding and processing of NF-kappaB2/p100 involve its phosphorylation at serines 866 and 870. Cell Signal 2006;18:1309-17
22. Saccani S, Pantano S, Natoli G. Modulation of NF-kappaB activity by exchange of dimers. Mol Cell 2003;11:1563-74
23. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 2006;72:1161-79
24. Song HY, Regnier CH, Kirschning CJ, et al. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 1997;94:9792-6
25. Yin L, Wu L, Wesche H, et al. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science 2001;291:2162-5
26. Sato S, Sanjo H, Takeda K, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005;6:1087-95
27. Shinkura R, Kitada K, Matsuda F, et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappab-inducing kinase. Nat Genet 1999;22:74-7
28. OMahony A, Lin X, Geleziunas R, Greene WC. Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol Cell Biol 2000;20:1170-8
29. Wittwer T, Schmitz ML. NIK and Cot cooperate to trigger NF-kappaB p65 phosphorylation. Biochem Biophys Res Commun 2008;371:294-7
30. Sanchez-Valdepenas C, Martin AG, Ramakrishnan P, et al. NF-kappaB-inducing kinase is involved in the activation of the CD28 responsive element through phosphorylation of c-Rel and regulation of its transactivating activity. J Immunol 2006;176:4666-74
31. Sanchez-Valdepenas C, Punzon C, San-Antonio B, et al. Differential regulation of p65 and c-Rel NF-kappaB transactivating activity by Cot, protein kinase C zeta and NIK protein kinases in CD3/CD28 activated T cells. Cell Signal 2007;19:528-37
32. Je JH, Lee JY, Jung KJ, et al. NF-kappaB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway. FEBS Lett 2004;566:183-9
33. Jijon H, Allard B, Jobin C. NF-kappaB inducing kinase activates NF-kappaB transcriptional activity independently of IkappaB kinase gamma through a p38 MAPK-dependent RelA phosphorylation pathway. Cell Signal 2004;16:1023-32
34. Jiang X, Takahashi N, Matsui N, et al. The NF-kappaB activation in lymphotoxin beta receptor signaling depends on the phosphorylation of p65 at serine 536. J Biol Chem 2003;278:919-26
35. Garceau N, Kosaka Y, Masters S, et al. Lineage-restricted function of nuclear factor kappaB-inducing kinase (NIK) in transducing signals via CD40. J Exp Med 2000;191:381-6
36. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 2004;21:477-89
37. Smith C, Andreakos E, Crawley JB, et al. NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts. J Immunol 2001;167:5895-903
38. Zarnegar B, Yamazaki S, He JQ, Cheng G. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci USA 2008;105:3503-8
39. Demchenko YN, Glebov OK, Zingone A, et al. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010;115:3541-52
40. Park YC, Burkitt V, Villa AR, et al. Structural basis for self-association and receptor recognition of human TRAF2. Nature 1999;398:533-8
41. Takeuchi M, Rothe M, Goeddel DV. Anatomy of TRAF2. Distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 1996;271:19935-42
42. Shi CS, Kehrl JH. Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). J Biol Chem 2003;278:15429-34
43. Deng L, Wang C, Spencer E, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000;103:351-61
44. Hauer J, Puschner S, Ramakrishnan P, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005;102:2874-9
45. Rothe M, Pan MG, Henzel WJ, et al. The TNFR2 - TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995;83:1243-52
46. Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30:689-700
47. Blankenship JW, Varfolomeev E, Goncharov T, et al. Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2. Biochem J 2009;417:149-60
48. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004;279:26243-50
49. Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002;416:345-7
50. Duckett CS, Thompson CB. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997;11:2810-21
51. Brown KD, Hostager BS, Bishop GA. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 2001;193:943-54
52. He JQ, Zarnegar B, Oganesyan G, et al. Rescue of TRAF3-null mice by p100 NF-kappaB deficiency. J Exp Med 2006;203:2413-18
53. Zarnegar BJ, Wang Y, Mahoney DJ, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008;9:1371-8
54. Vallabhapurapu S, Matsuzawa A, Zhang W, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008;9:1364-70
55. Grech AP, Amesbury M, Chan T, et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004;21:629-42
56. Yeh WC, Shahinian A, Speiser D, et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997;7:715-25
57. Nguyen LT, Duncan GS, Mirtsos C, et al. TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses. Immunity 1999;11:379-89
58. Habelhah H, Takahashi S, Cho SG, et al. Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J 2004;23:322-32
59. Tseng PH, Matsuzawa A, Zhang W, et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol 2010;11:70-5
60. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007;131:669-81
61. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682-93
62. Gardam S, Sierro F, Basten A, et al. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008;28:391-401
63. Xie P, Stunz LL, Larison KD, et al. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007;27:253-67
64. Razani B, Zarnegar B, Ytterberg AJ, et al. Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation. Sci Signal 2010;3:ra41
65. Lich JD, Williams KL, Moore CB, et al. Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. J Immunol 2007;178:1256-60
66. Ye Z, Lich JD, Moore CB, et al. ATP binding by monarch-1/NLRP12 is critical for its inhibitory function. Mol Cell Biol 2008;28:1841-50
67. Arthur JC, Lich JD, Aziz RK, et al. Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase. J Immunol 2007;179:6291-6
68. Qing G, Yan P, Qu Z, et al. Hsp90 regulates processing of NF-kappaB2 p100 involving protection of NF-kappaB-inducing kinase (NIK) from autophagy-mediated degradation. Cell Res 2007;17:520-30
69. Hu WH, Mo XM, Walters WM, et al. TNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activation. J Biol Chem 2004;279:35975-83
70. Yeung KC, Rose DW, Dhillon AS, et al. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 2001;21:7207-17
71. Lin X, Cunningham ET Jr, Mu Y, et al. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases. Immunity 1999;10:271-80
72. Bhattacharyya S, Borthakur A, Dudeja PK, Tobacman JK. Lipopolysaccharide-induced activation of NF-kappaB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations. Exp Cell Res 2010;316:3317-27
73. Bhattacharyya S, Borthakur A, Tyagi S, et al. B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation. J Biol Chem 2010;285:522-30
74. Hu WH, Pendergast JS, Mo XM, et al. NIBP, a novel NIK and IKKbeta-binding protein that enhances NF-kappaB activation. J Biol Chem 2005;280:29233-41
75. Jin X, Jin HR, Jung HS, et al. An atypical E3 ligase Zinc Finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via K63-linked ubiquitination. J Biol Chem 2010: published online 3 August 2010, doi:10.1074/jbc.M110.129551
76. Jin HR, Jin X, Lee JJ. Zinc finger protein 91 plays a key role in LIGHT-induced activation of noncanonical NF-kappaB pathway. Biochem Biophys Res Commun 2010;400:581-6
77. Bista P, Zeng W, Ryan S, et al. TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor. J Biol Chem 2010;285:12971-8
78. Sasaki Y, Calado DP, Derudder E, et al. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc Natl Acad Sci USA 2008;105:10883-8
79. Wang CY, Mayo MW, Korneluk RG, et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3
80. Xiao G, Sun SC. Negative regulation of the nuclear factor kappaB-inducing kinase by a cis-acting domain. J Biol Chem 2000;275:21081-5
81. Denz U, Haas PS, Wasch R, et al. State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer 2006;42:1591-600
82. Mortier J, Frederick R, Ganeff C, et al. Pyrazolo[4,3-c]isoquinolines as potential inhibitors of NF-kappaB activation. Biochem Pharmacol 2010;79:1462-72
83. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32
84. Mortier J, Masereel B, Remouchamps C, et al. NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening. Bioorg Med Chem Lett 2010;20:4515-20
85. Chen G, Cushing T, Fisher B, et al. Alkynyl alcohols as kinase inhibitors. WO2009158011; 2009
86. Goto Y, Sagara T, Fan W, et al. Novel 6-azaindole aminopyrimidine derivatives having NIK inhibitory activity. WO2010042337; 2010
87. Karrer U, Althage A, Odermatt B, et al. Immunodeficiency of alymphoplasia mice (aly/aly) in vivo: structural defect of secondary lymphoid organs and functional B cell defect. Eur J Immunol 2000;30:2799-807
88. Dingli D, Rajkumar SV. How best to use new therapies in multiple myeloma. Blood Rev 2010;24:91-100
89. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappaB activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276:22382-7
90. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302
91. OConnor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-8
92. Rossi JF, Moreaux J, Hose D, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstroms macroglobulinemia: a phase I study. Br J Cancer 2009;101:1051-8
93. Chauhan D, Neri P, Velankar M, et al. Targeting mitochondrial factor Smac/ DIABLO as therapy for multiple myeloma (MM). Blood 2007;109:1220-7
94. Greten FR, Arkan MC, Bollrath J, et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007;130:918-31
95. Lam LT, Davis RE, Ngo VN, et al. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci USA 2008;105:20798-803
96. Hideshima T, Chauhan D, Kiziltepe T, et al. Biologic sequelae of IkappaB kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 2009;113:5228-36